Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical retinoic acid

John L. Ubels, Vivian Rismondo, Henry F. Edelhauser

Research output: Contribution to journalArticle

Abstract

Several reports have appeared on the efficacy of topically applied 0.01% or 0.1% all-trans retinoic acid (0.04-0.4 millimolar) for treatment of xerophthalmia, conjunctival squamous metaplasia, and corneal epithelial erosions in humans and animals. An observation common to many of these studies is the occurrence of an adverse reaction to retinoic acid in the form of lid margin hyperemia and blepharoconjunctivitis. Since retinoic acid is biologically active at micro-molar to nanomolar concentrations, it may be possible to reduce side effects while maintaining therapeutic effectiveness by reducing the retinoic acid concentration in ophthalmic formulations. In the present study, topical 0.005% retinoic acid in petrolatum ointment reversed corneal keratinization in xerophthalmic, vitamin A-deficient rabbits in 3-4 days while 0.0005% (2 micromolar) retinoic acid ointment was effective in 4-6 days. Further clinical trials of topical retinoic acid for treatment of ocular surface disease should be conducted using micromolar concentrations of retinoic acid which are expected to maintain a therapeutic effect while reducing adverse reactions.

Original languageEnglish (US)
Pages (from-to)735-737
Number of pages3
JournalCurrent Eye Research
Volume6
Issue number5
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Xerophthalmia
Tretinoin
Rabbits
Ointments
Petrolatum
Eye Diseases
Hyperemia
Metaplasia
Therapeutic Uses
Vitamin A
Observation
Clinical Trials

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical retinoic acid. / Ubels, John L.; Rismondo, Vivian; Edelhauser, Henry F.

In: Current Eye Research, Vol. 6, No. 5, 1987, p. 735-737.

Research output: Contribution to journalArticle

Ubels, John L. ; Rismondo, Vivian ; Edelhauser, Henry F. / Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical retinoic acid. In: Current Eye Research. 1987 ; Vol. 6, No. 5. pp. 735-737.
@article{16276f28041c41b3864479a8412b5513,
title = "Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical retinoic acid",
abstract = "Several reports have appeared on the efficacy of topically applied 0.01{\%} or 0.1{\%} all-trans retinoic acid (0.04-0.4 millimolar) for treatment of xerophthalmia, conjunctival squamous metaplasia, and corneal epithelial erosions in humans and animals. An observation common to many of these studies is the occurrence of an adverse reaction to retinoic acid in the form of lid margin hyperemia and blepharoconjunctivitis. Since retinoic acid is biologically active at micro-molar to nanomolar concentrations, it may be possible to reduce side effects while maintaining therapeutic effectiveness by reducing the retinoic acid concentration in ophthalmic formulations. In the present study, topical 0.005{\%} retinoic acid in petrolatum ointment reversed corneal keratinization in xerophthalmic, vitamin A-deficient rabbits in 3-4 days while 0.0005{\%} (2 micromolar) retinoic acid ointment was effective in 4-6 days. Further clinical trials of topical retinoic acid for treatment of ocular surface disease should be conducted using micromolar concentrations of retinoic acid which are expected to maintain a therapeutic effect while reducing adverse reactions.",
author = "Ubels, {John L.} and Vivian Rismondo and Edelhauser, {Henry F.}",
year = "1987",
doi = "10.3109/02713688709034838",
language = "English (US)",
volume = "6",
pages = "735--737",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Treatment of corneal xerophthalmia in rabbits with micromolar doses of topical retinoic acid

AU - Ubels, John L.

AU - Rismondo, Vivian

AU - Edelhauser, Henry F.

PY - 1987

Y1 - 1987

N2 - Several reports have appeared on the efficacy of topically applied 0.01% or 0.1% all-trans retinoic acid (0.04-0.4 millimolar) for treatment of xerophthalmia, conjunctival squamous metaplasia, and corneal epithelial erosions in humans and animals. An observation common to many of these studies is the occurrence of an adverse reaction to retinoic acid in the form of lid margin hyperemia and blepharoconjunctivitis. Since retinoic acid is biologically active at micro-molar to nanomolar concentrations, it may be possible to reduce side effects while maintaining therapeutic effectiveness by reducing the retinoic acid concentration in ophthalmic formulations. In the present study, topical 0.005% retinoic acid in petrolatum ointment reversed corneal keratinization in xerophthalmic, vitamin A-deficient rabbits in 3-4 days while 0.0005% (2 micromolar) retinoic acid ointment was effective in 4-6 days. Further clinical trials of topical retinoic acid for treatment of ocular surface disease should be conducted using micromolar concentrations of retinoic acid which are expected to maintain a therapeutic effect while reducing adverse reactions.

AB - Several reports have appeared on the efficacy of topically applied 0.01% or 0.1% all-trans retinoic acid (0.04-0.4 millimolar) for treatment of xerophthalmia, conjunctival squamous metaplasia, and corneal epithelial erosions in humans and animals. An observation common to many of these studies is the occurrence of an adverse reaction to retinoic acid in the form of lid margin hyperemia and blepharoconjunctivitis. Since retinoic acid is biologically active at micro-molar to nanomolar concentrations, it may be possible to reduce side effects while maintaining therapeutic effectiveness by reducing the retinoic acid concentration in ophthalmic formulations. In the present study, topical 0.005% retinoic acid in petrolatum ointment reversed corneal keratinization in xerophthalmic, vitamin A-deficient rabbits in 3-4 days while 0.0005% (2 micromolar) retinoic acid ointment was effective in 4-6 days. Further clinical trials of topical retinoic acid for treatment of ocular surface disease should be conducted using micromolar concentrations of retinoic acid which are expected to maintain a therapeutic effect while reducing adverse reactions.

UR - http://www.scopus.com/inward/record.url?scp=0023258911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023258911&partnerID=8YFLogxK

U2 - 10.3109/02713688709034838

DO - 10.3109/02713688709034838

M3 - Article

VL - 6

SP - 735

EP - 737

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 5

ER -